Open Access
ISSN:0965-0407(print)
ISSN:1555-3906(online)
Publication Frequency:Monthly
Oncology Research is committed to publishing high-quality, innovative research that is focused on the entire range of basic, translational, and clinical cancer research, with a particular interest in cancer therapeutics, providing a new platform for the understanding, prevention, diagnosis, and treatment of cancer.
Science Citation Index Expanded (Clarivate Analytics): 2023 Impact Factor: 2.0; Scopus CiteScore (Impact per Publication 2023): 4.4; SNIP (Source Normalized Impact per Paper 2023): 0.473; Embase; PubMed Central; MEDLINE; EBSCO; Google Scholar; Proquest; Portico, etc.
Open Access
REVIEW
Oncology Research, Vol.32, No.8, pp. 1239-1256, 2024, DOI:10.32604/or.2024.052130
Abstract Glioblastoma multiforme (GBM) is an aggressive primary brain tumor characterized by extensive heterogeneity and vascular proliferation. Hypoxic conditions in the tissue microenvironment are considered a pivotal player leading tumor progression. Specifically, hypoxia is known to activate inducible factors, such as hypoxia-inducible factor 1alpha (HIF-1α), which in turn can stimulate tumor neo-angiogenesis through activation of various downward mediators, such as the vascular endothelial growth factor (VEGF). Here, we aimed to explore the role of HIF-1α/VEGF immunophenotypes alone and in combination with other prognostic markers or clinical and image analysis data, as potential biomarkers of GBM prognosis… More >
Open Access
REVIEW
Oncology Research, Vol.32, No.8, pp. 1257-1264, 2024, DOI:10.32604/or.2024.051653
Abstract The Kirsten rat sarcoma virus—son of sevenless 1 (KRAS-SOS1) axis drives tumor growth preferentially in pancreatic, colon, and lung cancer. Now, KRAS G12C mutated tumors can be successfully treated with inhibitors that covalently block the cysteine of the switch II binding pocket of KRAS. However, the range of other KRAS mutations is not amenable to treatment and the G12C-directed agents Sotorasib and Adragrasib show a response rate of only approximately 40%, lasting for a mean period of 8 months. One approach to increase the efficacy of inhibitors is their inclusion into proteolysis-targeting chimeras (PROTACs), which… More >
Graphic Abstract
Open Access
REVIEW
Oncology Research, Vol.32, No.8, pp. 1265-1285, 2024, DOI:10.32604/or.2024.048437
Abstract Uveal and conjunctival melanomas are relatively rare tumors; nonetheless, they pose a significant risk of mortality for a large number of affected individuals. The pathogenesis of melanoma at different sites is very similar, however, the prognosis for patients with ocular melanoma remains unfavourable, primarily due to its distinctive genetic profile and tumor microenvironment. Regardless of considerable advances in understanding the genetic characteristics and biological behaviour, the treatment of uveal and conjunctival melanoma remains a formidable challenge. To enhance the prospect of success, collaborative efforts involving medical professionals and researchers in the fields of ocular biology… More >
Graphic Abstract
Open Access
REVIEW
Oncology Research, Vol.32, No.8, pp. 1287-1308, 2024, DOI:10.32604/or.2024.049918
Abstract Aldo-keto reductases (AKRs) are a superfamily of enzymes that play crucial roles in various cellular processes, including the metabolism of xenobiotics, steroids, and carbohydrates. A growing body of evidence has unveiled the involvement of AKRs in the development and progression of various cancers. AKRs are aberrantly expressed in a wide range of malignant tumors. Dysregulated expression of AKRs enables the acquisition of hallmark traits of cancer by activating oncogenic signaling pathways and contributing to chemoresistance. AKRs have emerged as promising oncotherapeutic targets given their pivotal role in cancer development and progression. Inhibition of aldose reductase… More >
Open Access
REVIEW
Oncology Research, Vol.32, No.8, pp. 1309-1322, 2024, DOI:10.32604/or.2024.049743
Abstract Oncofertility is an extremely significant topic that is increasingly being discussed owing to increased evidence indicating that fertility preservation does not affect the treatment outcomes of patients with cancer but significantly contributes to preserving life quality. The effect of chemotherapy can range from minimal effects to complete ovarian atrophy. Limited data are available on the effects of monoclonal antibodies and targeted therapies on the ovaries and fertility. Temporary ovarian suppression by administering a gonadotropin-releasing hormone agonist (GnRHa) during chemotherapy decreases the gonadotoxic effect of chemotherapy, thereby diminishing the chance of developing premature ovarian insufficiency (POI).… More >
Graphic Abstract
Open Access
ARTICLE
Oncology Research, Vol.32, No.8, pp. 1323-1334, 2024, DOI:10.32604/or.2024.046965
Abstract Background: Fibroblast activation protein (FAP), a cell surface serine protease, plays roles in tumor invasion and immune regulation. However, there is currently no pan-cancer analysis of FAP. Objective: We aimed to assess the pan-cancer expression profile of FAP, its molecular function, and its potential role in head and neck squamous cell carcinoma (HNSC). Methods: We analyzed gene expression, survival status, immune infiltration, and molecular functional pathways of FAP in The Cancer Genome Atlas (TCGA) and Genotype Tissue Expression (GTEx) tumors. Furthermore, to elucidate the role of FAP in HNSC, we performed proliferation, migration, and invasion assays… More >
Open Access
ARTICLE
Oncology Research, Vol.32, No.8, pp. 1335-1346, 2024, DOI:10.32604/or.2024.044174
Abstract Long non-coding RNAs (lncRNAs) have been implicated in cancer progression and drug resistance development. Moreover, there is evidence that lncRNA HOX transcript antisense intergenic RNA (HOTAIR) is involved in colorectal cancer (CRC) progression. The present study aimed to examine the functional role of lncRNA HOTAIR in conferring radiotherapy resistance in CRC cells, as well as the underlying mechanism. The relative expression levels of HOTAIR were examined in 70 pairs of CRC tumor and para-cancerous tissues, as well as in radiosensitive and radioresistant samples. The correlations between HOTAIR expression levels and clinical features of patients with… More >
Open Access
ARTICLE
Oncology Research, Vol.32, No.8, pp. 1347-1357, 2024, DOI:10.32604/or.2024.046170
Abstract Hepatocellular carcinoma (HCC) poses a significant threat to human health. Resistance to sorafenib in the chemotherapy of HCC is a common and significant issue that profoundly impacts clinical treatment. While several members of the transmembrane (TMEM) protein family have been implicated in the occurrence and progression of HCC, the association between TMEM39b and HCC remains unexplored. This study revealed a significant overexpression of TMEM39b in HCC, which correlated with a poor prognosis. Subsequent investigation revealed that RAS-selective lethal 3 (RSL3) induced pronounced ferroptosis in HCC, and knocking down the expression of TMEM39b significantly decreased its More >
Open Access
ARTICLE
Oncology Research, Vol.32, No.8, pp. 1359-1368, 2024, DOI:10.32604/or.2024.043423
（This article belongs to the Special Issue: Signaling Pathway Crosstalk in Malignant Tumors: Molecular Targets and Combinatorial Therapeutics)
Abstract Multiple myeloma (MM) is a plasma cell malignancy and remains incurable as it lacks effective curative approaches; thus, novel therapeutic strategies are desperately needed. The study aimed to explore the therapeutic role of dihydromyricetin (DHM) in MM and explore its mechanisms. Human MM and normal plasma samples, human MM cell lines, and normal plasma cells were used for in vitro experiments. Cell counting kit-8 (CCK-8), flow cytometry, and trans-well assays were performed for the assessment of cell viability, apoptosis, migration, and invasion, respectively. Quantitative real-time polymerase chain reaction (qRT-PCR) was employed to assess the mRNA expression… More >
Graphic Abstract
Open Access
CORRECTION
Oncology Research, Vol.32, No.8, pp. 1369-1370, 2024, DOI:10.32604/or.2024.052652
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.8, pp. 1371-1371, 2024, DOI:10.32604/or.2024.055030
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.8, pp. 1373-1373, 2024, DOI:10.32604/or.2024.055031
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.8, pp. 1375-1375, 2024, DOI:10.32604/or.2024.055032
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.8, pp. 1377-1377, 2024, DOI:10.32604/or.2024.055033
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.8, pp. 1379-1379, 2024, DOI:10.32604/or.2024.055034
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.8, pp. 1381-1381, 2024, DOI:10.32604/or.2024.055035
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.8, pp. 1383-1383, 2024, DOI:10.32604/or.2024.055036
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.8, pp. 1385-1385, 2024, DOI:10.32604/or.2024.055037
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.8, pp. 1387-1387, 2024, DOI:10.32604/or.2024.055039
Abstract This article has no abstract. More >
Login
Register
Submit a Paper
Propose a Special lssue
